The Downside of Looking on the Bright Side: Viropharma's Optimism Hurts Vancocin Case
This article was originally published in RPM Report
Executive Summary
Viropharma’s challenge to FDA’s approval of generic versions of Vancocin hasn’t gotten very far in court. One reason: the company’s own statements to investors undercut one of the key components of a preliminary injunction suit.
You may also be interested in...
Musical Tables in Generic Drug Litigation
Generic drug litigation remains a prominent part of food and drug law practices. But with the growing complexity of the case law—and the blurring lines within industry—it is very hard to predict which client and which attorney will be on what side. Back-to-back hearings on Provigil and Vancocin make that clear.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.